Supply Chain Intelligence

Zenas BioPharma, Inc. Supply Chain

ZBIO supply chain intelligence for Zenas BioPharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ZBIO ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

10Suppliers
11Customers
2Debt Items
20Related Chains

Zenas BioPharma, Inc. Suppliers

TickerNameConfidenceEvidence
PHARMAKON-ADVISORS-LP PHARMAKON-ADVISORS-LP 92% The Company alleviated the uncertainty associated with its ability to continue as a going concern through the execution of its senior secured term loan, the issuance of Convertible Notes and the seni…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN grap…
AZN AstraZeneca PLC 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
CELG-RI CELG-RI 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates…
GSK GSK plc 72% Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are…
GSK GSK plc 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates a…
NVSEF Novartis AG 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
XNCR Xencor, Inc. 72% Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR g…

Zenas BioPharma, Inc. Customers

TickerNameConfidenceEvidence
INNOCARE-PHARMA-INC INNOCARE-PHARMA-INC 85% ar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely impacted; ● ​ We have relied and expect to continue to rely on third parties…
ZAI-LAB-HONG-KONG-LIMITED ZAI-LAB-HONG-KONG-LIMITED 85% the Company granted Zai an exclusive sublicense to develop, manufacture and commercialize ZB001 and related programs in greater China
AZN AstraZeneca PLC 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU fo…
CELG-RI CELG-RI 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from …
DNTH Dianthus Therapeutics, Inc. 72% Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercial…
GSK GSK plc 72% Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK grap…
GSK GSK plc 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates a…
NVSEF Novartis AG 72% embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact…

Zenas BioPharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZBIO-DEBT-13734 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
ZBIO-DEBT Debt stack $266.8M 90% Market cache reports total debt of $266.8M.

Zenas BioPharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zenas BioPharma, Inc..

Zenas BioPharma, Inc. Ownership

HolderNameConfidenceEvidence
ZBIO-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 140 tracked holders.

Zenas BioPharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BEAM Beam Therapeutics Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CLYM Climb Bio, Inc. 100.00 1 ['spend']
DAWN Day One Biopharmaceuticals Inc 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
DEO Diageo plc 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
View ZBIO supply chain intel →

Explore the full interactive supply chain map for Zenas BioPharma, Inc..

Open ZBIO supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map